glp-1 management platforms startups GLP-1 Market Trends and Global Forecasts Report 2025: A 5 Startups Looking to Compete

This phase is about assessment, not results

Based on clinical trial data: Common: Nausea (22-40%most common complaint) Flushing (14-17%) Headache (9-14%) Injection site reactions Less common: Vomiting Fatigue Dizziness Serious concerns: Transient blood pressure increases Hyperpigmentation with frequent use Contraindicated in uncontrolled hypertension or cardiovascular disease The nausea can be dose-limiting for some individuals

Palmeira, R

There is even one documented case though at this point its isolated of someone developing a tumor , diagnosed by their medical team as mucosal melanoma, in the front portion of their upper jawbone after using a nasal spray containing melanotan II (9)